Status:
UNKNOWN
Prevalence and Incidence of COVID-19 Infection in Patients With Chronic Plaque Psoriasis on Immunosuppressant Therapy
Lead Sponsor:
Universita di Verona
Collaborating Sponsors:
Azienda Ospedaliera Universitaria Integrata Verona
Conditions:
Coronavirus Infection
Eligibility:
All Genders
18-75 years
Brief Summary
This study will assess the prevalence and incidence of COVID-19 infection in patients with chronic plaque psoriasis on immunosuppressant therapy.
Detailed Description
The ongoing COVID-19 pandemic has hit Northern Italy (including the Veneto region) particularly hard, causing several deaths and putting a huge strain on the Italian National Healthcare System. In the...
Eligibility Criteria
Inclusion
- Group 1
- Aged 18 to 75 years old
- Individuals with a clinical diagnosis of moderate-to-severe chronic plaque psoriasis confirmed by the Investigator
- Continuous immunosuppressive therapy (etanercept, adalimumab, infliximab, ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab, apremilast, methotrexate, ciclsoporin, acitretin) for the past 3 months
- Is willing and able to sign informed consent to participate
Exclusion
- Patients unwilling to undergo noasopharyngeal swab
- Inability to give informed consent
- Group 2
- Inclusion Criteria:
- Aged 18 to 75 years old
- Partner of a patient with psoriasis enrolled in the study
- Is willing and able to sign informed consent to participate
Key Trial Info
Start Date :
April 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2020
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04324866
Start Date
April 1 2020
End Date
December 1 2020
Last Update
March 27 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.